## GILD: Gilead Sciences, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($116.72)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. VestGen Advisors LLC Lowers Holdings in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251204T132801 | Somewhat-Bullish | Relevance: 100%
- VestGen Advisors LLC significantly reduced its stake in Gilead Sciences, Inc. by 93.2% in Q2, selling 25,709 shares and retaining 1,866 shares valued at $207,000. Despite this, Wall Street analysts maintain a "Moderate Buy" rating with a consensus price target of $130.65 for Gilead, which recently beat EPS and revenue estimates and announced a $0.79 quarterly dividend. However, insider selling has been notable, with the CEO and another insider offloading a combined 38,000 shares worth millions.

**2. Channing Capital Management LLC Purchases 43,875 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251204T101109 | Somewhat-Bullish | Relevance: 100%
- Channing Capital Management LLC significantly increased its stake in Gilead Sciences, Inc. by purchasing 43,875 additional shares, bringing their total holdings to 101,884 shares valued at $11,296,000. This comes amidst other institutional investors modifying their positions and analysts setting new price targets for GILD. The article also details Gilead Sciences' recent financial performance, upcoming dividend, and insider trading activity.

**3. Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline**
- Source: MSN | 20251204T091041 | Bullish | Relevance: 100%
- Mizuho has increased its price target for Gilead Sciences (GILD) after a recent KOL event clarified the Biktarvy timeline, suggesting potential for stronger mid-decade revenue. The analyst anticipates continued growth for Biktarvy, driven by its effective and tolerable profile in the HIV market. Despite competitive pressures, Gilead's robust pipeline and strategic focus are expected to support its long-term market position.

**4. Invesco Ltd. Buys 3,394,330 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251203T101843 | Somewhat-Bullish | Relevance: 100%
- Invesco Ltd. increased its holdings in Gilead Sciences, Inc. by 33.5% in the second quarter, acquiring an additional 3,394,330 shares. This purchase brings Invesco's total ownership to 13,521,228 shares, valued at approximately $1.5 billion, and represents 1.09% of the biopharmaceutical company. The article also details significant buying and selling activity by other institutional investors and company insiders, alongside recent analyst ratings and financial performance data for Gilead Sciences.

**5. Gilead Sciences (NASDAQ:GILD) CEO Sells $1,265,400.00 in Stock**
- Source: MarketBeat | 20251202T232225 | Somewhat-Bullish | Relevance: 100%
- Gilead Sciences CEO Daniel Patrick O'day sold 10,000 shares of company stock for $1,265,400 on November 28, reducing his stake by 1.72%. This follows similar sales in October and September, indicating a pattern of insider selling. The company recently reported beating Q3 earnings and revenue estimates and declared a quarterly dividend.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Needham | $140 | $133 | +5% |
| 2025-11-13 | Scotiabank | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Needham | main | Buy |
| 2025-11-13 | Scotiabank | init | Sector Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($10.00M) |
| Sells | 13 ($5.91M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (-0.3%)
- Blackrock Inc.: 9.4% (+1.2%)
- FMR, LLC: 4.9% (+0.6%)
- State Street Corpora: 4.8% (-0.2%)
- Capital World Invest: 3.6% (-2.4%)

### Key Risks

1. Insider selling cluster: $5.9M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.23 indicates undervaluation relative to growth. Quality metrics strong (ROE 41%, ROA 13%, margin 28%). Balance sheet: $4.0B free cash flow. Analyst sentiment positive (1 raises, avg +5%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $154.7B |
| Beta | 0.33 |
| 52W Range | $88.57 - $128.70 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.23 |
| Forward P/E | 14.0 |
| Current P/E | 15.0 |
| YoY Growth | 7.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -3.0% to -4.1% (-1.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.1pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). MACD histogram bearish (-0.53), momentum weakening. RSI neutral at 48. OFD pattern: -FTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.11% (CS: 10) | Weak |
| RSI_14 | 47.8 | Neutral |
| MACD Histogram | -0.53 | Bearish |
| vs SMA20 | 0.985x | Below |
| vs SMA50 | 1.018x | Above |
| vs SMA200 | 1.086x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $122.62
- **Stop Loss:** $116.72 (4.8% risk)
- **Target:** $128.52 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 84
- **Position Value:** $10,300.08
- **Portfolio %:** 10.30%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-10 (Est: $1.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.14 | $2.47 | +15.7% |
| 2025Q2 | $1.96 | $2.01 | +2.7% |
| 2025Q1 | $1.78 | $1.81 | +1.9% |
| 2024Q4 | $1.70 | $1.90 | +11.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*